A-01 Registration at the conference venue Tuesday 14:00-18:00 |
A-02 Welcome reception with drinks and light snacks (no dinner) Tuesday 18:00-19:30 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-02 Welcome and introduction Wednesday 08:45-09:00 |
B-03 Jeff Sachs Pharmacometrics: A shot in the arm for vaccine discovery and development ~or~ Vaccines are not immune to the charms of pharmacometrics Wednesday 09:00-09:45 |
B-05 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 09:50-11:15 |
B-06 Marjorie Imperial Stratified medicine approaches for drug susceptible tuberculosis patients Wednesday 11:15-11:35 |
B-07 Stefanie Hennig Repeated time-to-event models support that Pseudomonas aeruginosa infection increase the risk of acquiring Aspergillus in young children with cystic fibrosis Wednesday 11:35-11:55 |
B-08 María García-Cremades Individual level data meta-analysis from HIV pre-exposure prophylaxis (PrEP) clinical trials Wednesday 11:55-12:15 |
B-09 Lunch Wednesday 12:15-13:45 |
B-10 Nicky Best Use of informative priors in model-informed drug development Wednesday 13:45-14:30 |
B-11 Chiara Nicolò Machine learning combined to mechanistic modeling of differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth Wednesday 14:30-14:50 |
B-12 Sebastien Benzekry Machine learning versus mechanistic modeling for prediction of metastatic relapse in breast cancer Wednesday 14:50-15:10 |
B-13 Coffee break, poster and software session I: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:10-16:40 |
B-15 João Abrantes Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII Wednesday 16:45-17:05 |
B-16 Belén Pérez Solans Model-based characterization of neutrophil dynamics in children receiving busulfan or treosulfan for hematopoietic stem cell transplant conditioning Wednesday 17:05-17:25 |
B-17 Zinnia Parra-Guillen Disease pharmacokinetic-pharmacodynamic (PKPD) modelling to support the development of gene therapy treatments for rare diseases Wednesday 17:25-17:45 |
B-18 Pascal Chanu A disease progression model for geographic atrophy Wednesday 17:45-18:05 |
C-01 Moustafa M. A. Ibrahim Competing risks analysis of the Finnish diabetes prevention study Thursday 08:30-08:55 |
C-02 Sebastiaan Goulooze Novel pharmacometric techniques to quantify and prevent iatrogenic withdrawal in children Thursday 08:55-09:20 |
C-03 Elena Tosca Dynamic Energy Budget (DEB) based models of tumor-in-host growth inhibition and cachexia onset Thursday 09:20-09:45 |
C-04 Presentation LBS awards Thursday 09:45-09:50 |
C-05 Special announcement Thursday 09:50-09:55 |
C-06 Coffee break, poster and software session I: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 09:55-11:20 |
C-07 Kristin Karlsson Regulatory model-informed drug discovery and development in EU – News flash and examples Thursday 11:20-12:05 |
C-08 Sylvie Retout A model-based extrapolation enabled labelling of emicizumab in haemophilia A paediatric patients <1 year old despite lack of clinical data Thursday 12:05-12:25 |
C-09 ACoP Announcement Thursday 12:25-12:30 |
C-10 Lunch Thursday 12:30-14:00 |
C-11 ISoP Student Community meet-and-greet during lunch Thursday 12:30-14:00 |
C-12 Theodoros Papathanasiou Model based optimization of dose-finding studies for drug-combinations. Thursday 14:00-14:20 |
C-13 Antonio Goncalves Model Averaging in viral dynamic models Thursday 14:20-14:40 |
C-14 Mohammed Cherkaoui Rbati A liver model for chemoprotection against malaria Thursday 14:40-15:00 |
C-15 Xiao Zhu A cohesive model framework of receptor pharmacology: beyond the Emax model Thursday 15:00-15:20 |
C-16 WCoP Announcement Thursday 15:20-15:25 |
C-17 Coffee break, poster and software session I: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:25-16:50 |
C-18 Alison Margolskee Exploratory graphics (xGx): promoting the purposeful exploration of PKPD data Thursday 16:50-17:10 |
C-19 Marc Cerou Performance of npde for the evaluation of joint model with time to event data Thursday 17:10-17:30 |
C-20 Social event Thursday 18:30-01:00 |
D-01 Aurelia de Vries Schultink Prospective evaluation of Therapeutic Drug Monitoring of endoxifen: feasibility of observational and randomized trials. Friday 09:20-09:40 |
D-02 Coralie Tardivon Association between tumor size kinetics and survival in advanced urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow-up Friday 09:40-10:00 |
D-03 Jiajie Yu A new approach to predict PFS in Ovarian Cancer based on tumor growth dynamics. Friday 10:00-10:20 |
D-04 Preview of PAGE 2020 Friday 10:20-10:25 |
D-05 Coffee break Friday 10:25-11:00 |
D-06 Julie Janssen A semi-physiological framework to predict changes in pharmacokinetics of cytotoxic drugs in pregnant women Friday 11:00-11:20 |
D-07 James Lu Integrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia Friday 11:20-11:40 |
D-08 Closing remarks Friday 11:40-11:50 |
D-09 Audience input for potential PAGE 2020 topics Friday 11:50-12:05 |
I-01 Nurul Azrin Abd Rahman A population pharmacokinetic/pharmacodynamic (PK/PD) model of the investigational antimalarial drug Artefenomel in a Plasmodium vivax Volunteer-Infection Study Wednesday 09:50-11:15 |
I-02 Mahmoud Abdelwahab Clofazimine population pharmacokinetics in South African patients with drug resistant tuberculosis Wednesday 09:50-11:15 |
I-03 Khaled Abduljalil Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice Wednesday 09:50-11:15 |
I-04 Anson Abraham Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design? Wednesday 09:50-11:15 |
I-05 Ahmad Abuhelwa Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression Wednesday 09:50-11:15 |
I-06 Ahmed Aliyu Abulfathi External validation of a para-aminosalicylic acid population pharmacokinetics model using the ncappc R package Wednesday 09:50-11:15 |
I-07 Oliver Ackaert Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects Wednesday 09:50-11:15 |
I-08 Bambang Adiwijaya Component score models of HAMD were more predictive than total score models Wednesday 09:50-11:15 |
I-09 Jae Eun Ahn Longitudinal Model-Based Meta-Analysis for Liver Biomarkers and Biopsy Endpoints in Patients with Non-Alcoholic Fatty Liver Disease Wednesday 09:50-11:15 |
I-10 Maurice Ahsman A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy Wednesday 09:50-11:15 |
I-11 Marie Alexandre Modeling viral rebound in HIV therapeutic vaccine studies Wednesday 09:50-11:15 |
I-12 Joachim Almquist Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation Wednesday 09:50-11:15 |
I-13 Jokha AL-Qassabi Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment Wednesday 09:50-11:15 |
I-14 Hesham Al-Sallami The use of a Bayesian dosing tool to optimise enoxaparin treatment: a pilot clinical study Wednesday 09:50-11:15 |
I-15 Vincent Aranzana-Climent Use of a semi-mechanistic PK-PD model to quantify the combination effect of polymyxin B and minocycline against polymyxin-resistant Acinetobacter baumannii Wednesday 09:50-11:15 |
I-16 Million Arefayene Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011) Wednesday 09:50-11:15 |
I-17 Leticia Arrington An R package for Automated Generation of Item Response Theory Model NONMEM Control File Wednesday 09:50-11:15 |
I-18 Usman Arshad A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients Wednesday 09:50-11:15 |
I-19 Muhammad Waqar Ashraf Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers Wednesday 09:50-11:15 |
I-20 Magnus Åstrand nonmem2R: An R-package for Visual Predictive Checks and Goodness-of-fit Plots Wednesday 09:50-11:15 |
I-21 Ioanna Athanasiadou Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis Wednesday 09:50-11:15 |
I-22 Linda Aulin Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents Wednesday 09:50-11:15 |
I-23 Rami Ayoun Alsoud Simultaneous Assessment of Time-to-positivity and Colony-forming Unit in tuberculosis patients under high-dose rifampicin therapy Wednesday 09:50-11:15 |
I-24 Geraldine Celliere Straightforward dose adaptation simulations with Simulx, the simulator of the MonolixSuite Wednesday 09:50-11:15 |
I-25 LE Ba Hai Population pharmacokinetic model of sorafenib and application to a case report Wednesday 09:50-11:15 |
I-26 Junjie Ding Pharmacometric drug adherence approach and its application in a clinical setting Wednesday 09:50-11:15 |
I-27 Vanessa Baier Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism Wednesday 09:50-11:15 |
I-28 Pavel Balazki A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models. Wednesday 09:50-11:15 |
I-29 Violeta Balbas-Martinez Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn's Disease Wednesday 09:50-11:15 |
I-30 Irina Baltcheva ggPMX: an open-source R package for pharmacometric model diagnostic plots Wednesday 09:50-11:15 |
I-31 Maddlie Bardol Population pharmacokinetics of fentanyl in very preterm infants Wednesday 09:50-11:15 |
I-32 Christian Bartels Getting a better description of treatment effects for time to event data using PKPD modelling Wednesday 09:50-11:15 |
I-33 Roberta Bartolucci Optimal design of paediatric clinical trials: the Macitentan case study Wednesday 09:50-11:15 |
I-34 Carla Bastida Fernández Assessment of tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients Wednesday 09:50-11:15 |
I-35 Francesco Bellanti Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs Wednesday 09:50-11:15 |
I-36 Amina Bensalem Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis Wednesday 09:50-11:15 |
I-37 Linnea Bergenholm Predicting plasma and liver exposure in humans with a pharmacokinetic model for a GalNAc3-conjugated antisense oligonucleotide using sparse monkey data Wednesday 09:50-11:15 |
I-38 Aliénor Bergès Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case Wednesday 09:50-11:15 |
I-39 Martin Bergstrand Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling Wednesday 09:50-11:15 |
I-40 Jan Berkhout Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia Wednesday 09:50-11:15 |
I-41 Julie Bertrand Model-based approach for group sequential and adaptive designs in parallel and cross-over bioequivalence studies Wednesday 09:50-11:15 |
I-42 Robert Bies On the Multilemma of reproducibility: Stochastic or Deterministic or Stochastic and Deterministic Wednesday 09:50-11:15 |
I-43 Bruno Bieth Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer Wednesday 09:50-11:15 |
I-44 Roberto Bizzotto Conditional linear mixed-effect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study Wednesday 09:50-11:15 |
I-45 Irina Bondareva Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data Wednesday 09:50-11:15 |
I-46 Guillaume Bonnefois A new computational approach to match control subjects to renal impaired patients in pharmacokinetic studies Wednesday 09:50-11:15 |
I-47 Elisa Borella Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia Wednesday 09:50-11:15 |
I-48 Agnieszka Borsuk-De Moor The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits Wednesday 09:50-11:15 |
I-49 Thomas Bouillon Model predictive control with Bayesian updates (MPC) is more robust to model misspecification, compared to standard Bayesian control (sEBE) for Therapeutic Drug Management (TDM). Investigation in a cohort of 315 patients receiving tacrolimus during the first 14d after renal transplantation. Wednesday 09:50-11:15 |
I-50 Marion Bouillon-Pichault Model-based meta-analysis of efficacy and safety of anti-PD1 compounds in melanoma Wednesday 09:50-11:15 |
I-51 Muriel Boulton What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)? Wednesday 09:50-11:15 |
I-52 Ari Brekkan Viggosson Model based support to biosimilarity assessment planning – A case study of pegfilgrastim Wednesday 09:50-11:15 |
I-53 Astrid Broeker Parameter uncertainty in small datasets – evaluation approaches at their limit Wednesday 09:50-11:15 |
I-54 Vincent Buchheit Data scientists for improving efficiency and quality of quantitative clinical pharmacology analyses Wednesday 09:50-11:15 |
I-55 Núria Buil Bruna Can monocyte counts predict future drug-induced neutropenia toxicities? Wednesday 09:50-11:15 |
I-56 David Busse Analysis of target-site distribution of meropenem in morbidly obese and non-obese patients using nonlinear mixed-effects modelling Wednesday 09:50-11:15 |
I-57 Antonio Cabal Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery Wednesday 09:50-11:15 |
I-58 Unai Caballero Pharmacodynamic modelling to evaluate the in vitro activity of amphotericin B against Candida auris Wednesday 09:50-11:15 |
I-59 Elisa Calvier Alirocumab population pharmacokinetics in Chinese patients using priors Wednesday 09:50-11:15 |
I-60 Tim Cardilin Tumor Static Exposure for anticancer combinations in early drug discovery Wednesday 09:50-11:15 |
I-61 Fernando Carreño Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia Wednesday 09:50-11:15 |
I-62 Jantine Brussee Model-based dose optimization of ivermectin to achieve equivalent exposure coverage in children and adults Wednesday 09:50-11:15 |
I-63 Blesson Chacko Why patients may not benefit from effective oncology drugs Wednesday 09:50-11:15 |
I-64 Dong Woo Chae Predictive model of postoperative nausea and vomiting in patients treated with Fentanyl-based intravenous patient controlled analgesia Wednesday 09:50-11:15 |
I-65 Anne Chain A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia Wednesday 09:50-11:15 |
I-66 Anna Chan Kwong Bridging studies: handling covariates models using the Prior approach Wednesday 09:50-11:15 |
I-67 Christophe Chassagnole A precision dosing application for docetaxel in metastatic prostate cancer Wednesday 09:50-11:15 |
I-68 Estelle Chasseloup Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part II – control of the type I error with real placebo data Wednesday 09:50-11:15 |
I-69 Jonathan Chauvin Novel user-friendly applications for dose individualization of sunitinib and imatinib Wednesday 09:50-11:15 |
I-70 Alexia Chauzy Semi-mechanistic pharmacodynamics modeling of aztreonam-avibactam combination to understand its antimicrobial activity against multidrug-resistant Gram-negative bacteria Wednesday 09:50-11:15 |
I-71 Viji Chelliah Mechanistic models of cancer-immune cycle and immunotherapies Wednesday 09:50-11:15 |
I-72 Lu Chen Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis Wednesday 09:50-11:15 |
I-73 Maxwell Chirehwa Population pharmacokinetics of cycloserine dosed as terizidone in drug-resistant tuberculosis patients Wednesday 09:50-11:15 |
I-74 Siri Kalyan Chirumamilla Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients Wednesday 09:50-11:15 |
I-75 Palang Chotsiri Mechanistic modelling of primaquine pharmacokinetics, gametocyte clearance, and mosquito infectivity Wednesday 09:50-11:15 |
I-76 Emmanuelle Comets Conditional non-parametric bootstrap for non-linear mixed effect models Wednesday 09:50-11:15 |
I-77 Valerie Cosson Target-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy Wednesday 09:50-11:15 |
I-78 Perrine Courlet Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV. Wednesday 09:50-11:15 |
I-79 Sinziana Cristea Untangling maturation functions for kidney transporters using a combined population pharmacokinetics and physiology-based pharmacokinetics approach Wednesday 09:50-11:15 |
I-80 Salvatore D'Agate Population Pharmacokinetics and Effect of Variable Renal Function on the Exposure to Aciclovir in Term and Pre-term Neonates Wednesday 09:50-11:15 |
I-81 Kim Dao Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells Wednesday 09:50-11:15 |
I-82 Mailys De Sousa Mendes Transporter inhibition: modelling in-vitro Transwell assays Wednesday 09:50-11:15 |
I-83 Eva Maria del Amo Paez Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes Wednesday 09:50-11:15 |
I-84 Francesca Del Bene Intratympanic drug administration: a challenge for PK modelling Wednesday 09:50-11:15 |
I-85 Laurence Del Frari Population modelling and simulations of binimetinib pharmacokinetics in subjects with hepatic impairment to explore optimal dosing regimen using total and unbound binimetinib exposures Wednesday 09:50-11:15 |
I-86 Oleg Demin Jr Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling Wednesday 09:50-11:15 |
I-87 Laure Deyme Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue Wednesday 09:50-11:15 |
I-88 Sofie Dhaese The use of optimal experimental design to inform a clinical trial on non-linearity of piperacillin clearance in critically ill patients. Wednesday 09:50-11:15 |
I-89 Richard Dimelow PK Precision Estimation to support the Design of a Pediatric Study of Belimumab Administered Subcutaneously Wednesday 09:50-11:15 |
II-01 Åsa Kragh Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease Wednesday 15:10-16:40 |
II-02 Markus Krauß Mice with human livers improve First-in-Human prediction of pharmacokinetics Wednesday 15:10-16:40 |
II-03 Rukmini Kumar Quantitative Systems Pharmacology (QSP) tools to aid in model development and communication: Vantage QSP Modeling Tools (VQM-Tools) Wednesday 15:10-16:40 |
II-04 Hanna Kunina Diabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data Wednesday 15:10-16:40 |
II-05 Sofiene Laarif Quantitative modeling of inter-lesion and inter-organ variability of tumor size Wednesday 15:10-16:40 |
II-06 Jennifer Lang Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions Wednesday 15:10-16:40 |
II-07 Silvia Maria Lavezzi Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis Wednesday 15:10-16:40 |
II-08 Jean Lavigne Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population Wednesday 15:10-16:40 |
II-09 Jacob Leander Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations Wednesday 15:10-16:40 |
II-10 Donghwan Lee Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation Wednesday 15:10-16:40 |
II-11 Woo Yul Lee Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients Wednesday 15:10-16:40 |
II-12 Soyoung Lee Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012 Wednesday 15:10-16:40 |
II-13 Hyun A Lee A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans Wednesday 15:10-16:40 |
II-14 So Jin Lee The new era of pharmacokinetic/pharmacodynamic modeling and simulation in drug development in Korea Wednesday 15:10-16:40 |
II-15 Anja Lehmann Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach Wednesday 15:10-16:40 |
II-16 Rory Leisegang Establishing evidence for improved outcomes for HIV+ patients receiving antiretroviral drugs through home delivery Wednesday 15:10-16:40 |
II-17 Giulia Lestini Handling dropouts in longitudinal observational studies – an illustration of a workflow from data preparation to model building and model diagnostics in Alzheimer’s disease Wednesday 15:10-16:40 |
II-18 Yisheng Li A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling Wednesday 15:10-16:40 |
II-19 Patrick Lilienthal Mathematical modeling of RBC count dynamics after blood loss Wednesday 15:10-16:40 |
II-20 Dan Liu Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the most influential parameters of a Minimal PBPK Model of Midazolam Wednesday 15:10-16:40 |
II-21 Feiyan Liu Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide Wednesday 15:10-16:40 |
II-22 Carolina Llanos-Paez Implementation of event time distribution as a random effect in time-to-event analysis Wednesday 15:10-16:40 |
II-23 Rasmus Jansson Löfmark Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement Wednesday 15:10-16:40 |
II-24 Aurelie Lombard Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation Wednesday 15:10-16:40 |
II-25 Dominik Lott Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod Wednesday 15:10-16:40 |
II-26 Qiang Lu Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects Wednesday 15:10-16:40 |
II-27 Inga Ludwig A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy to Support Full or Partial Extrapolation in Pediatric Drug Development Wednesday 15:10-16:40 |
II-28 Ulrich Ruben Luecht Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine Wednesday 15:10-16:40 |
II-29 Nicolas Luyckx Improving the performances of clinical trial simulations in Simulo using compiled code Wednesday 15:10-16:40 |
II-30 Yassine Kamal Lyauk Dose Finding in Clinical Development of 60 FDA-Approved Drugs Compared to the Learning versus Confirming Paradigm Wednesday 15:10-16:40 |
II-31 Sreenath M Krishnan A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients Wednesday 15:10-16:40 |
II-32 Guangda Ma Evaluating the influence of genotype on warfarin dose predictions made using a theory-based PKPD model. Wednesday 15:10-16:40 |
II-33 Panos Macheras On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants Wednesday 15:10-16:40 |
II-34 Paolo Magni Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics? Wednesday 15:10-16:40 |
II-35 Mats Magnusson Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis Wednesday 15:10-16:40 |
II-36 Corinna Maier Quantifying the uncertainty: informative decision-support in individualised chemotherapy Wednesday 15:10-16:40 |
II-37 Victor Mangas-Sanjuan Population Pharmacokinetic and exposure-efficacy Markov modelling of enzymatic activity in Gaucher disease patients treated with enzyme replacement therapy Wednesday 15:10-16:40 |
II-38 Nicolás Marco Ariño Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery Wednesday 15:10-16:40 |
II-39 Fatima Zahra Marok Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine Wednesday 15:10-16:40 |
II-40 Frederico Martins Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection. Wednesday 15:10-16:40 |
II-41 Paolo Mazzei Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma Wednesday 15:10-16:40 |
II-42 Mark Meerson Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease Wednesday 15:10-16:40 |
II-43 Christophe Meille Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin Wednesday 15:10-16:40 |
II-44 Nicola Melillo Global sensitivity analysis of a physiologically based pulmonary absorption model Wednesday 15:10-16:40 |
II-45 France Mentré New version of PFIM for optimal design in nonlinear mixed effects models using R S4 Wednesday 15:10-16:40 |
II-46 Matilde Merino-Sanjuán Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5'-deoxy-5-fluorouridine (5'-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer Wednesday 15:10-16:40 |
II-47 Danica Michalickova Pharmacokinetics of phenobarbital in neonates on extracorporeal membrane oxygenation Wednesday 15:10-16:40 |
II-48 Robin Michelet A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance Wednesday 15:10-16:40 |
II-49 Iris Minichmayr Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy Wednesday 15:10-16:40 |
II-50 Jonathan Mochel A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species Wednesday 15:10-16:40 |
II-51 Daniel Moj Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach Wednesday 15:10-16:40 |
II-52 Camille Riff Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia Wednesday 15:10-16:40 |
II-53 Anna Mc Laughlin Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics Wednesday 15:10-16:40 |
II-54 Flora Musuamba Tshinanu Dose optimization based on control and system theory: Case of Meropenem Wednesday 15:10-16:40 |
II-55 Tadakatsu Nakamura A Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms Wednesday 15:10-16:40 |
II-56 Ricardo Nalda-Molina Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease. Wednesday 15:10-16:40 |
II-57 Srividya Neelakantan Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients Wednesday 15:10-16:40 |
II-58 Ida Neldemo The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times Wednesday 15:10-16:40 |
II-59 Bernard Ngara A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents. Wednesday 15:10-16:40 |
II-60 Laurent Nguyen Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies Wednesday 15:10-16:40 |
II-61 Laura Zwep Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data Wednesday 15:10-16:40 |
II-62 Joakim Nyberg Implicit and efficient handling of missing covariate information using full random effects modelling Wednesday 15:10-16:40 |
II-63 Boram Ohk Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics Wednesday 15:10-16:40 |
II-64 Andrés Olivares-Morales Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker Wednesday 15:10-16:40 |
II-65 Sean Oosterholt Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose Wednesday 15:10-16:40 |
II-66 Fernando Ortega Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth Wednesday 15:10-16:40 |
II-67 Taniya Paiboonvong Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid Wednesday 15:10-16:40 |
II-68 Semra Palic Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis Wednesday 15:10-16:40 |
II-69 Robert Palmér A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations Wednesday 15:10-16:40 |
II-70 Hyeonsoo Park A population pharmacokinetic model of Glimepiride(Amaryl®) Wednesday 15:10-16:40 |
II-71 Christophe Passot A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset. Wednesday 15:10-16:40 |
II-72 Nathalie Perdaems Translational PK-RO modelling for a mAb to predict the outcome of the first in human study Wednesday 15:10-16:40 |
II-73 Carlos Perez-Ruixo Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) Wednesday 15:10-16:40 |
II-74 Soumya Perinparajah Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Wednesday 15:10-16:40 |
II-75 Thomas Peyret Development of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism Wednesday 15:10-16:40 |
II-76 Chiara Piana Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human Wednesday 15:10-16:40 |
II-77 Philippe Pierrillas PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients Wednesday 15:10-16:40 |
II-78 Nikhil Pillai Single objective genetic algorithm based approach for optimal population pharmacokinetic/pharmacodynamics (PK/PD) model selection for tumor growth response Wednesday 15:10-16:40 |
II-79 Vikram Prabhakar QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies Wednesday 15:10-16:40 |
II-80 Sudeep Pradhan Evaluation of study designs to test the intact nephron hypothesis Wednesday 15:10-16:40 |
II-81 Mélanie Prague In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies Wednesday 15:10-16:40 |
II-82 Luna Prieto Garcia Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis Wednesday 15:10-16:40 |
II-83 Alicja Puszkiel Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism Wednesday 15:10-16:40 |
II-84 Rajith Rajoli PBPK Modelling of Atovaquone Long-acting Injectable Formulations Wednesday 15:10-16:40 |
II-85 Chetan Rathi Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor Wednesday 15:10-16:40 |
II-86 Michael Reed Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform Wednesday 15:10-16:40 |
II-87 Javier Reig-López Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software. Wednesday 15:10-16:40 |
II-88 Isabel Reinecke Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis Wednesday 15:10-16:40 |
II-89 Dinko Rekic Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight Wednesday 15:10-16:40 |
III-01 Clémence Rigaux An approach for reducing the sample sizes of pediatric trials in Type 2 Diabetes Mellitus: longitudinal analysis versus standard analyses Thursday 09:55-11:20 |
III-02 Matthew Riggs M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus Thursday 09:55-11:20 |
III-03 François Riglet Bayesian individual dynamic predictions of biomarkers and risk of event in joint modelling (with uncertainty): a comparison between Stan, Monolix and NONMEM Thursday 09:55-11:20 |
III-04 Christer Rimmler Evaluating the Influence of Cardiopulmonary Bypass on the Pharmacokinetics of Cefuroxime using PBPK and PopPK Models Thursday 09:55-11:20 |
III-05 Viktor Rognås Bounded Integer approach to model time-varying SOFA scores from patients with carbapenem resistant infections Thursday 09:55-11:20 |
III-06 Federico Romano Predictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine Thursday 09:55-11:20 |
III-07 Daniel Röshammar Assessment of expected drug exposure relative maximum safety limits in early phase studies Thursday 09:55-11:20 |
III-08 Ryosuke Shimizu Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia Thursday 09:55-11:20 |
III-10 Tomohisa Saito The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients Thursday 09:55-11:20 |
III-11 Louis Sandra A population pharmacokinetic model for propofol in (pre)term neonates and infants independently accounting for size, gestational age (GA) and postnatal age (PNA). Thursday 09:55-11:20 |
III-12 Marina Savelieva Modeling decline in cognition to decline in function in Alzheimer’s disease Thursday 09:55-11:20 |
III-13 Annika Schneider A PBPK approach for simulating the effect of liver cirrhosis on drug PK Thursday 09:55-11:20 |
III-14 Rik Schoemaker Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr Thursday 09:55-11:20 |
III-15 Jérémy Seurat Comparison of Phase I combination therapy designs by clinical trial simulations to evaluate early tumor shrinkage Thursday 09:55-11:20 |
III-16 Dmitry Shchelokov Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies Thursday 09:55-11:20 |
III-17 Soyoung Shin Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption Thursday 09:55-11:20 |
III-18 Christian Siebel Development of an adaptive dosing approach for doxorubicin in paediatric cancer patients Thursday 09:55-11:20 |
III-19 Iryna Sihinevich Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study Thursday 09:55-11:20 |
III-20 Florian Simon A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics Thursday 09:55-11:20 |
III-21 Noppaket Singkham Pharmacogenetics-Based Population Pharmacokinetic Analysis for Dosing Optimization of Ritonavir-Boosted Atazanavir in Thai adult HIV-Infected Patients Thursday 09:55-11:20 |
III-22 Jaydeep Sinha Extension of the Janmahasatian fat-free mass model to account for ethnicity-related bias Thursday 09:55-11:20 |
III-23 Erik Sjögren A PBPK Framework to Predict Drug Exposure in Malnourished Children Thursday 09:55-11:20 |
III-24 Eunjung Song Selection of optimal study design based on the bioequivalence simulation study in highly variable drugs Thursday 09:55-11:20 |
III-25 Elena Soto Population Pharmacokinetic (PopPK) Modelling and Simulation of Pregabalin to Support Dose Recommendation in Paediatric Patients 1 month to <4 years of Age with Partial Onset Seizures (POS) Thursday 09:55-11:20 |
III-26 Tomás Sou Translational PK and PKPD modelling for the analysis of preclinical in-vitro and in-vivo studies to predict efficacious human dose of apramycin Thursday 09:55-11:20 |
III-27 Viktoria Stachanow Does dried blood spot data enrich our understanding of hydrocortisone pharmacokinetics in paediatric patients with adrenal insufficiency? Thursday 09:55-11:20 |
III-28 Felix Stader Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly Thursday 09:55-11:20 |
III-29 Gabriel Stillemans Simultaneous population pharmacokinetic modeling of darunavir and cobicistat in a cohort of HIV patients Thursday 09:55-11:20 |
III-30 Mark Stroh Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology Thursday 09:55-11:20 |
III-31 Herbert Struemper Population Pharmacokinetics of Belimumab Administered Intravenously in Children with Systemic Lupus Erythematosus Thursday 09:55-11:20 |
III-32 Sabine Stuebler Systems biology model of the mucosal immune system Thursday 09:55-11:20 |
III-33 Suein Choi contribution of trough concentration data for the evaluation of multiple-dose pharmacokinetics Thursday 09:55-11:20 |
III-34 Jesper Sundell Pharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV Thursday 09:55-11:20 |
III-35 Budi Octasari Susanto Translational Model-Informed Selection of Tuberculosis Drug Combination Regimens for Early Clinical Development Thursday 09:55-11:20 |
III-36 Hadi Taghvafard Modeling (a)symmetry of concentration-effect curves Thursday 09:55-11:20 |
III-37 Hiroyuki Takita The dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell Thursday 09:55-11:20 |
III-38 Lénaïg Tanneau Evaluating potential link between liver enzyme abnormalities and bedaquiline exposure in multi-drug resistant tuberculosis patients Thursday 09:55-11:20 |
III-39 Joel Tarning Severe acute malnutrition results in lower exposure in children treated with artemether-lumefantrine for uncomplicated malaria Thursday 09:55-11:20 |
III-40 David Ternant Revisiting target-mediated elimination of therapeutic antibodies: the irreversible binding approximation Thursday 09:55-11:20 |
III-41 Mita Thapar Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients. Thursday 09:55-11:20 |
III-42 Anders Thorsted Model-based translation from piglets to healthy volunteers: Prediction of TNF-α and IL-6 time-courses in human endotoxin challenge studies Thursday 09:55-11:20 |
III-43 Tjokosela Tikiso A pooled analysis of abacavir pharmacokinetics in HIV-infected African children: the effect of age, malnutrition, and common concomitant co-medications. Thursday 09:55-11:20 |
III-44 Pauline Traynard New library of double absorptions PK models for the MonolixSuite, application to veralipride pharmacokinetics Thursday 09:55-11:20 |
III-45 Carlos Traynor Towards personalised medicine in Non-Small Cell Lung Cancer: design of a forecasting model of disease-progression to overall survival. Thursday 09:55-11:20 |
III-46 Iñaki F. Trocóniz A modelling platform for onco-immunological drugs in early drug development Thursday 09:55-11:20 |
III-47 Denise Feick Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim Thursday 09:55-11:20 |
III-48 Sami Ullah Population pharmacokinetics of cefepime in critically ill patients with and without impaired renal function Thursday 09:55-11:20 |
III-49 Parth Upadhyay Exploring the Relationship Between Midazolam Concentrations And Level Of Sedation In Critically-Ill Mechanically Ventilated Children Using Markov Modelling Thursday 09:55-11:20 |
III-50 David Uster Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A Thursday 09:55-11:20 |
III-51 Pavan Vaddady Application of Bayesian Methodology to Inform Imipenem/Relebactam Pediatric Study Design Thursday 09:55-11:20 |
III-52 Cristina Vaghi Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor Thursday 09:55-11:20 |
III-53 Stijn van Beek Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients Thursday 09:55-11:20 |
III-54 Arthur Van De Vyver in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics. Thursday 09:55-11:20 |
III-55 Louvina van der Laan Pharmacokinetics and drug-drug interactions of lamivudine and abacavir administered with antituberculosis drugs in HIV-infected children with multidrug-resistant tuberculosis Thursday 09:55-11:20 |
III-56 Jan-Stefan van der Walt A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics Thursday 09:55-11:20 |
III-57 Tamara van Donge Methadone dosing strategies in preterm neonates can be simplified Thursday 09:55-11:20 |
III-58 Rob van Wijk Nanoscale pharmacokinetics and pharmacodynamics of isoniazid treatment of tuberculosis in zebrafish larvae Thursday 09:55-11:20 |
III-59 Filippo Venezia Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib) Thursday 09:55-11:20 |
III-60 Diego Vera Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein Thursday 09:55-11:20 |
III-61 Luka Verrest Exploring variability in paromomycin pharmacokinetics in East African visceral leishmaniasis patients Thursday 09:55-11:20 |
III-62 Ludwig Vincent How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors Thursday 09:55-11:20 |
III-63 Janet Wade Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR Thursday 09:55-11:20 |
III-64 Ulrika Wählby Hamrén Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling Thursday 09:55-11:20 |
III-65 Wenyi Wang Physiological Response to Endotoxin Infusion in the Piglet: Modelling of changes in hemodynamic outcomes Thursday 09:55-11:20 |
III-66 Shijun Wang Comparison of approaches for estimating covariate effects in full random effects models Thursday 09:55-11:20 |
III-67 Zhigang Wang A Pharmacokinetic-Pharmacodynamic model built on in vitro data predict the antibacterial effect of polymyxin B against Klebsiella pneumoniae in vivo Thursday 09:55-11:20 |
III-68 Linda Wanika Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases Thursday 09:55-11:20 |
III-69 Shayne Watson Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies Thursday 09:55-11:20 |
III-70 Sebastian Weber Qualifying drug dosing regimens in pediatrics using Gaussian Processes Thursday 09:55-11:20 |
III-71 Ferdinand Weinelt A joint pharmacokinetic model of piperacillin/tazobactam including mechanistic renal clearance in critically ill patients Thursday 09:55-11:20 |
III-72 Gustaf Wellhagen Modelling UACR as a clinical endpoint Thursday 09:55-11:20 |
III-73 Quirin Werthner Network-based mathematical modelling of HPV transmission and cervical cancer in Germany. Thursday 09:55-11:20 |
III-74 Sebastian Wicha TDMxR: an open-source package for model-based therapeutic drug monitoring in R Thursday 09:55-11:20 |
III-75 Mélanie Wilbaux Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data Thursday 09:55-11:20 |
III-76 Justin Wilkins Population Pharmacokinetics analysis of M5717, a novel antimalarial agent Thursday 09:55-11:20 |
III-77 Francis Williams Ojara Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy Thursday 09:55-11:20 |
III-78 Jan-Georg Wojtyniak Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6 Thursday 09:55-11:20 |
III-79 Dan Wright Kinetic-pharmacodynamic models in the setting of non-linear drug elimination Thursday 09:55-11:20 |
III-80 Xia Li A Physiologically-Based Pharmacokinetic Model of Voriconazole Thursday 09:55-11:20 |
III-81 Rujia Xie Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Pediatric and Adult Patients with Invasive Fungal Infections Thursday 09:55-11:20 |
III-82 Estelle Yau A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models Thursday 09:55-11:20 |
III-83 Anyue Yin Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing Thursday 09:55-11:20 |
III-84 Jinqiu Yin Pharmacokinetic-pharmacodynamic modeling of colistin against Pseudomonas aeruginosa-associated biofilm infections Thursday 09:55-11:20 |
III-85 Sirin Yonucu Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach Thursday 09:55-11:20 |
III-86 Jurij Aguiar Zdovc Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors Thursday 09:55-11:20 |
III-87 Yang Zhang Ways to improve the efficiency of pharmacometric model implemented in R using deSovle – an example with a PK model for ADC Thursday 09:55-11:20 |
III-88 Chenyan Zhao Colistin to overcome resistance to ciprofloxacin - Quantifying combined effects of colistin and ciprofloxacin against four E. coli strains with different ciprofloxacin susceptibility in an in silico PKPD model Thursday 09:55-11:20 |
III-89 Xuan Zhou Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds Thursday 09:55-11:20 |
III-90 Tom Zwart Population pharmacokinetics and limited sampling of iohexol as a renal function marker Thursday 09:55-11:20 |
IV-01 Christiane Dings Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study Thursday 15:25-16:50 |
IV-02 Anne-Gaelle Dosne Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma Thursday 15:25-16:50 |
IV-03 Erwin Dreesen A population pharmacokinetic and exposure-response model to support therapeutic drug monitoring during vedolizumab induction therapy Thursday 15:25-16:50 |
IV-04 Ronan Duchesne Identifiability in nonlinear mixed effect models: the example of in vitro erythropoiesis Thursday 15:25-16:50 |
IV-05 Vincent Duval A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab. Thursday 15:25-16:50 |
IV-06 Dimitra Eleftheriadou Aluminium biokinetics: Elucidating the speciation kinetics of the aluminium-citrate system in vitro. Thursday 15:25-16:50 |
IV-07 Douglas J. Eleveld Aging and maturation as a reliability problem: The Weibull distribution and age- and maturation-adjustment functions Thursday 15:25-16:50 |
IV-08 Esther Encinas Use of modeling and simulation methods to support the generic application of a vaginal delivery system Thursday 15:25-16:50 |
IV-09 Aline Engbers Postnatal age, gestational age and small for gestational age drive the pharmacokinetics of ibuprofen enantiomers in very preterm neonates with patent ductus arteriosus Thursday 15:25-16:50 |
IV-10 Muhammad Faisal Simultaneous semi-mechanistic population pharmacokinetic analysis of enalapril and enalaprilat in serum and urine following the administration of child appropriate oro-dispersible mini-tablets. Thursday 15:25-16:50 |
IV-11 Undine Falkenhagen Structural model selection: Is the chi-square distribution appropriate for likelihood ratio tests? Thursday 15:25-16:50 |
IV-12 Alan Faraj Drug effect of clofazimine on persisting mycobacteria explain an unexpected increase in bacterial load from patients Thursday 15:25-16:50 |
IV-13 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
IV-14 Anam Fayyaz Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes Thursday 15:25-16:50 |
IV-15 Rebekka Fendt Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations Thursday 15:25-16:50 |
IV-16 Valentina Fermanelli Correlation structure of Apolipoprotein A4, C3, E kinetics parameters Thursday 15:25-16:50 |
IV-17 Chiara Fornari Importance of stability analysis when using non-linear semi-mechanistic models to describe drug-induced haematotoxicity Thursday 15:25-16:50 |
IV-18 Jose Francis A semi-mechanistic model to characterise the influence of nevirapine- and lopinavir/ritonavir-based therapy on artemether and dihydroartemisinin exposure Thursday 15:25-16:50 |
IV-19 Yu Fu Hemodynamic systems model to characterize cardiovascular drug effects Thursday 15:25-16:50 |
IV-20 Aline Fuchs Assessment of translation of PKPD relationship from animal to human for malaria compounds Thursday 15:25-16:50 |
IV-21 Laura Fuhr Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab Thursday 15:25-16:50 |
IV-22 Masato Fukae Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker Thursday 15:25-16:50 |
IV-23 Fanny Gallais Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies Thursday 15:25-16:50 |
IV-24 Fiona G. Gao Prediction of human pharmacokinetics of subcutaneously administered insulin formulations Thursday 15:25-16:50 |
IV-25 Kamunkhwala Gausi Pharmacokinetics of isoniazid preventative therapy among HIV-infected pregnant women in high tuberculosis incidence settings Thursday 15:25-16:50 |
IV-26 Sergey Gavrilov Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer Thursday 15:25-16:50 |
IV-27 Peter Gennemark Determination of antisense oligonucleotide tissue half-life Thursday 15:25-16:50 |
IV-28 Eva Germovsek A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations Thursday 15:25-16:50 |
IV-29 Bill Gillespie Torsten: Stan functions for pharmacometric applications. New functionality including within chain parallel computation. Thursday 15:25-16:50 |
IV-30 Anais Glatard Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling Thursday 15:25-16:50 |
IV-31 Ferran Gonzalez Pharmacokinetic model development for total and free vancomycin in critically ill children Thursday 15:25-16:50 |
IV-32 Ignacio Gonzalez-Garcia Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836) Thursday 15:25-16:50 |
IV-33 Mario Gonzalez Sales Assembling pharmacometric datasets in R: the puzzle package Thursday 15:25-16:50 |
IV-34 Katharina Martha Götz Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation Thursday 15:25-16:50 |
IV-35 Iztok Grabnar Oxcarbazepine and its active metabolite 10-monohydroxycarbamazepine clearance maturation in paediatric patients with epilepsy Thursday 15:25-16:50 |
IV-36 Silvia Grandoni Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats Thursday 15:25-16:50 |
IV-37 Ana-Marija Grisic Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study Thursday 15:25-16:50 |
IV-38 Jinju Guk Modelling the dose-effect relationship between DAV132, an activated charcoal based product, and fecal concentration of moxifloxacin in healthy volunteers Thursday 15:25-16:50 |
IV-39 Tingjie Guo Exploring practical limitations of model-based Bayesian dose optimization in intensive care patients Thursday 15:25-16:50 |
IV-40 Stefanie Hamacher Population pharmacokinetics of cannabidiol in healthy subjects Thursday 15:25-16:50 |
IV-41 Felix Hammann Population pharmacokinetics and generation of dosing nomograms of daptomycin at a Swiss university hospital Thursday 15:25-16:50 |
IV-42 Lutz Harnisch Dose Selection Process for Younger Children Participating in a Phase 3 Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-occlusive Crisis in Hospitalized Patients With Sickle Cell Disease Thursday 15:25-16:50 |
IV-43 Paul Healy PKPD bridging and extrapolation of efficacy for the use of gabapentin and tramadol in paediatric chronic pain. Thursday 15:25-16:50 |
IV-44 Guenter Heimann An Industry Perspective on Extrapolation in Pediatric Drug Development: A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy. Thursday 15:25-16:50 |
IV-45 Farina Hellmann Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example Thursday 15:25-16:50 |
IV-46 Emilie Hénin Therapeutic drug monitoring strategies for Envarsus in de novo renal transplant patients using population modelling and simulations Thursday 15:25-16:50 |
IV-47 Charlotte Kloft Review of NMLE articles published in clinical journals with a higher impact factor Thursday 15:25-16:50 |
IV-48 Thomas Henthorn A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data Thursday 15:25-16:50 |
IV-49 Lukas Kovar Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers Thursday 15:25-16:50 |
IV-50 Anneke Himstedt Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches. Thursday 15:25-16:50 |
IV-51 Richard Höglund Multidrug-resistant genotypes are associated with therapeutic failure of antimalarial therapy in Cambodia; a pharmacometric approach Thursday 15:25-16:50 |
IV-52 Nick Holford Rational dosing of caffeine using target concentration intervention to improve treatment of apnea of prematurity Thursday 15:25-16:50 |
IV-53 Chih-hsuan Hsin Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects Thursday 15:25-16:50 |
IV-54 Ka Ho, Matthew Hui Evaluation of Parameter Estimation when Fitting a Mixture Model with Covariate Effects using NONMEM Thursday 15:25-16:50 |
IV-55 Ziad Hussein Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia Thursday 15:25-16:50 |
IV-56 Eman Ibrahim Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort. Thursday 15:25-16:50 |
IV-57 Hiroyuki Iida Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice Thursday 15:25-16:50 |
IV-58 Luis Ilia Quantitative comparison of in vitro and in vivo variability of microdialysis experiments using nonlinear mixed-effects modelling on the example of linezolid Thursday 15:25-16:50 |
IV-59 Khalid Iqbal Modelling tissue pharmacokinetics: A comparison of empiric and mechanistic PBPK modelling approaches of different complexity exemplified with moxifloxacin Thursday 15:25-16:50 |
IV-60 Itziar Irurzun-Arana ACESO (A Cancer Evolution Simulation Optimizer) Thursday 15:25-16:50 |
IV-61 Kris Oliver Jalusic Pharmacokinetics of vancomycin in the cerebrospinal fluid in critically ill patients Thursday 15:25-16:50 |
IV-62 Petra Jauslin Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis Thursday 15:25-16:50 |
IV-64 Jin Jin Model-informed artificial intelligence (AI) solution enabling real-time predictions: towards next generation modeling Thursday 15:25-16:50 |
IV-65 Mats Jirstrand A challenge model of TNFα turnover with LPS provocations and drug intervention Thursday 15:25-16:50 |
IV-66 Curtis Johnston M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM) Thursday 15:25-16:50 |
IV-67 Daniel Jonker The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin Thursday 15:25-16:50 |
IV-68 Felix Jost Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia Thursday 15:25-16:50 |
IV-69 Fabian Jung Simulation of the environmental exposure to fenofibrate nanomaterials based on in vitro- and in silico methods Thursday 15:25-16:50 |
IV-70 Wannee kantasiripitak A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis Thursday 15:25-16:50 |
IV-71 Evangelos Karakitsios A methodology to estimate population pharmacokinetic parameters from aggregate concentration-time data and its application to gevokizumab. Thursday 15:25-16:50 |
IV-72 Vangelis Karalis An In Vitro – In Vivo Simulation Methodology for Predicting the Outcome of Bioequivalence Studies Thursday 15:25-16:50 |
IV-73 Eleni Karatza Investigation of the impact of population parameters describing gastric emptying on bioequivalence metrics Thursday 15:25-16:50 |
IV-74 Tatiana Karelina Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects Thursday 15:25-16:50 |
IV-75 Adrien Tessier Use of mixture models in pharmacometric model-based analysis of confirmatory trials: part I - simulation study evaluating type I error and power of proof-of-concept trials Thursday 15:25-16:50 |
IV-76 Hidefumi Kasai Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab Thursday 15:25-16:50 |
IV-77 Takayuki Katsube Evaluation of Variance-based Global Sensitivity Analysis for Covariate Effects Thursday 15:25-16:50 |
IV-78 Aida Kawuma Dolutegravir pharmacokinetics in co-administration with rifampicin. Thursday 15:25-16:50 |
IV-79 Ron Keizer Continuous learning in model-informed precision dosing: a case study Thursday 15:25-16:50 |
IV-80 Zackary Kenz Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model Thursday 15:25-16:50 |
IV-81 Yun Kim A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects Thursday 15:25-16:50 |
IV-82 NaYoung Kim Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy Thursday 15:25-16:50 |
IV-83 Seoyoung Kim Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale Thursday 15:25-16:50 |
IV-84 Dohyun Kim Optimization of dosing strategy for Colistin using population pharmacokinetic model based on the Bayesian inference Thursday 15:25-16:50 |
IV-85 Lena Klopp-Schulze Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development Thursday 15:25-16:50 |
IV-86 Franziska Isabelle Kluwe Model-based characterisation of nonlinear voriconazole pharmacokinetics following two different routes of administration Thursday 15:25-16:50 |
IV-87 Lisa Alina Kneller Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach Thursday 15:25-16:50 |
IV-88 Stephan Koehne-Voss A comparison of relative exposure estimates from single trough, multiple trough, and full population PK sampling designs Thursday 15:25-16:50 |
IV-89 Galina Kolesova Application of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies Thursday 15:25-16:50 |
S-01 Niklas Hartung A flexible and transparent MATLAB framework for empirical and mechanistic pharmacometric modelling During entire meeting |
S-02 Rikard Nordgren Perl speaks NONMEM (PsN) During entire meeting |